Production and Purification of Non Replicative Canine Adenovirus Type 2 Derived Vectors
December 3rd, 2013
6.9K views
These past 15 years, canine adenovirus type 2 (CAV2)-derived vectors have proven their efficiency to transduce cells in vitro and in vivo and are widely used for vaccination and gene therapy. Here, we describe a procedure to construct, produce and purify CAV2 vectors, giving rise to high-titer viral suspensions.
Overview
This article describes a procedure for constructing, producing, and purifying canine adenovirus type 2 (CAV2)-derived vectors. These vectors are effective for transducing cells both in vitro and in vivo, making them valuable for vaccination and gene therapy applications.
Key Study Components
Area of Science
- Gene therapy
- Viral vectors
- Vaccination techniques
Background
- Canine adenovirus type 2 (CAV2) is utilized for its efficiency in cell transduction.
- High-titer viral suspensions are essential for effective applications.
- The use of CAV2 vectors has expanded significantly over the past 15 years.
- These vectors are applicable in both research and clinical settings.
Purpose of Study
- To provide a detailed methodology for constructing CAV2 vectors.
- To enhance the understanding of viral vector production.
- To facilitate the use of CAV2 vectors in various biomedical applications.
Methods Used
- Cloning the gene of interest into a shuttle plasmid.
- Obtaining a recombinant genomic plasmid via homologous recombination.
- Producing and amplifying recombinant viruses in a trans complementing cell line.
- Purifying and concentrating the recombinant virus for applications.
Main Results
- Successful construction and purification of high-titer CAV2 vectors.
- Demonstration of viral transduction in rodent brain using immunofluorescence confocal microscopy.
- Establishment of a reliable protocol for vector production.
- Potential applications in gene therapy and vaccination highlighted.
Conclusions
- CAV2-derived vectors are effective tools for gene therapy and vaccination.
- The described methodology can be utilized for various research applications.
- Future studies may explore additional applications of CAV2 vectors.
Frequently Asked Questions
What are CAV2 vectors used for?
CAV2 vectors are used for gene therapy and vaccination due to their efficiency in transducing cells.
How are CAV2 vectors produced?
They are produced by cloning the gene of interest into a shuttle plasmid and amplifying it in a trans complementing cell line.
What is the significance of high-titer viral suspensions?
High-titer viral suspensions are crucial for effective transduction in both in vitro and in vivo applications.
What techniques are used to visualize viral transduction?
Immunofluorescence confocal microscopy is used to visualize viral transduction in the rodent brain.
Can CAV2 vectors be used in clinical settings?
Yes, CAV2 vectors have potential applications in clinical settings for gene therapy and vaccination.
What are the steps involved in purifying CAV2 vectors?
The steps include cloning, homologous recombination, amplification, and purification of the recombinant virus.
Executive Industry Relevance
Canine adenovirus type 2 (CAV2) vectors address the challenge of pre-existing immunity in human populations, enabling reliable gene transfer for vaccine and therapeutic development. Their high-titer production and broad tropism support mechanistic de-risking in CNS-targeted programs and predictive confidence in translational neuroscience and vaccinology pipelines.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of protein function in defined brain regions via retrograde axonal transport.
- Operational Value: Supports target validation through efficient transduction of neuronal populations in vivo.
Screening & Assay Development
- Scientific Value: Produces quantifiable viral stocks for consistent dose-response in antiviral or immunogenicity screening.
- Operational Value: Standardized purification via cesium chloride gradients ensures batch-to-batch reproducibility for assay inputs.
Translational & Preclinical Research
- Scientific Value: Facilitates disease-relevant modeling by enabling transgene delivery to specific CNS circuits.
- Operational Value: High-titer stocks (>10^10 infectious particles/mL) support scalable preclinical dosing studies.
Pipeline & Workflow Integration
CAV2 vector production fits within the discovery continuum from target validation through lead identification to preclinical evaluation, particularly for neurotropic or immunomodulatory candidates.
- Discovery Biology: Enables pathway clarification by delivering transgenes to discrete neuronal populations for functional interrogation.
- Screening: Purified viral suspensions provide standardized inputs for high-content transduction assays in primary or stem cell-derived models.
- Analytics: Endpoint dilution titration yields quantitative infectious unit measurements essential for comparative potency assessment.
- Translational Research: Retrograde transport capability supports biomarker-aligned target engagement studies in disease-relevant CNS pathways.
- Enterprise Reuse: Platform amenable to serial cloning of diverse expression cassettes via shuttle plasmid recombination, enabling multi-target screening campaigns.
Operational & Enterprise Impact
- Scientific Value: Predictive confidence in target mechanism through precise spatial and temporal transgene expression in vivo.
- Operational Value: Ultracentrifugation-based purification yields pure, concentrated viral stocks suitable for GLP-compliant toxicology studies.
- Strategic Value: Reduces biological risk in late-stage development by avoiding pre-existing immunity confounders in human seropositive populations.
- Portfolio Impact: Enables risk-adjusted prioritization of CNS-targeted biologics with validated delivery efficiency in large animal models.
Implementation Considerations
- Requires molecular biology expertise in plasmid construction and homologous recombination in bacterial strains.
- Dependent on ultracentrifugation equipment and cesium chloride gradients for viral purification and empty particle removal.
- Necessitates BSL-2 containment and trained personnel for handling viral lysates and large-scale amplification in adherent cell factories.
- Adaptation across species requires validation of transduction efficiency and immune profile in target preclinical models.
- Practical limitation: Viral yield is dependent on CPE consistency in DK-E1 cells, necessitating monitoring and potential amplification round adjustments.
Biopharma FAQs
Why does endpoint dilution titration matter for target validation?
Endpoint dilution titration using the Reed and Muench method quantifies infectious units, enabling precise dosing for target engagement studies in vivo. This supports reproducible mechanistic de-risking by correlating vector dose with transgene expression levels in defined brain regions.
How does homologous recombination enable independent variable isolation in vector construction?
Homologous recombination in E. coli BJ5183 inserts the expression cassette into the CAV2 genome while deleting E1 regions, isolating the transgene as the sole variable. This ensures that observed phenotypes in transduction assays reflect the gene of interest, not vector backbone effects.
What quantitative dependent variable measurements enable predictive confidence in transduction efficiency?
Immunofluorescence confocal microscopy quantifies transgene-positive cells, providing a dependent variable for assessing transduction efficiency. In rodent brain, this enables correlation of vector dose with neuronal transduction rates (e.g., 40–50% in dentate gyrus) for predictive modeling.
Why do replication requirements matter for cross-functional collaboration in viral production?
Multiple viral amplification rounds in DK-E1 cells are required to achieve high-titer stocks, ensuring consistency between production batches. This reproducibility supports reliable handoff between vector production, analytical QC, and preclinical teams for aligned go/no-go decisions.
What statistical analysis capabilities are required before implementing cesium chloride gradient purification?
Visual identification of opalescent bands and side-puncture collection require training to distinguish mature viral particles from empty capsids. No formal statistical test is specified, but operator proficiency is critical to avoid contamination with non-infectious upper-band particles that would skew titer measurements.
Chapters in this video
0:05
Title
1:40
Transfection of Recombinant CAV2 Genomic Plasmid onto DK-E1 Cells
3:25
Propagation of Recombinant CAV2
5:48
Large-scale CAV2 Purification
10:07
Titration of CAV2 by End-point Dilution
11:04
Results: Production, Purification, and Application of CAV2
14:04
Conclusion
